Related Experiment Video

Updated: Jan 5, 2026

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection
09:01

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection

Published on: December 10, 2013

8.2K

Infant Respiratory Syncytial Virus Bronchiolitis and Subsequent Risk of Pneumonia, Otitis Media, and Antibiotic

Andrew Abreo1, Pingsheng Wu1,2, Brittney M Donovan1

  • 1Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|October 21, 2019
PubMed

Insights

Infant respiratory syncytial virus (RSV) bronchiolitis in early infancy is linked to higher risks of pneumonia and ear infections later. These findings highlight the potential benefits of RSV vaccination for long-term infant respiratory health.

Area of Science:

  • Pediatrics
  • Infectious Diseases
  • Public Health

Background:

  • Respiratory Syncytial Virus (RSV) is a common cause of lower respiratory tract infections in infants.
  • Bronchiolitis, often caused by RSV, is a significant pediatric respiratory illness.
  • Understanding the long-term sequelae of infant RSV bronchiolitis is crucial for public health strategies.

Purpose of the Study:

  • To investigate the association between infant respiratory syncytial virus (RSV) bronchiolitis in the first six months of life and subsequent respiratory and infectious conditions.
  • To evaluate the impact of early-life RSV bronchiolitis on the incidence of pneumonia, otitis media, and antibiotic use in the second six months of life.

Main Methods:

  • Retrospective cohort study design.
  • Analysis of health records to identify infants diagnosed with RSV bronchiolitis within the first six months of life.
  • Comparison of the incidence of pneumonia, otitis media, and antibiotic prescription fills between infants with and without a history of early RSV bronchiolitis.

Main Results:

  • Infants with RSV bronchiolitis in the first six months of life had significantly increased odds of developing pneumonia in the second six months.
  • A higher likelihood of otitis media was observed in infants with a history of early RSV bronchiolitis.
  • Infants previously diagnosed with RSV bronchiolitis were more likely to receive antibiotic prescriptions in the subsequent six months.

Conclusions:

  • Early-life RSV bronchiolitis is associated with an elevated risk of subsequent respiratory infections and conditions, including pneumonia and otitis media.
  • The findings underscore the potential public health benefits of interventions, such as future RSV vaccination programs, in mitigating the long-term respiratory health burden in infants.
  • Further research into the long-term respiratory outcomes following RSV bronchiolitis is warranted.

Keywords:
bronchiolitisinfant antibioticsotitis mediapneumoniarespiratory syncytial virus

More Related Videos

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

15.5K
Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses11:48

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Published on: April 4, 2019

16.9K

Related Concept Videos

Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
680
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
747
Pulmonary Cycle: Exhalation01:17

Pulmonary Cycle: Exhalation

In terms of human respiration, the act of expelling air, known as exhalation (or expiration), operates on the principle of pressure gradients. During expiration, the pressure within the lungs exceeds that of the surrounding atmosphere. Under normal conditions, quiet breathing involves passive exhalation and is free of muscular contractions. This is because the exhalation process is driven by the natural elastic recoil of the lungs and chest wall, both of which have an inherent tendency to...
2.9K
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
3.3K
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
2.4K
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
709